Interactive Features

Test Your Knowledge

Quiz: Is Cervicovaginal Microbiota Type a Risk Factor for Ovarian Cancer?

12/21/2020

True or false: Type O cervicovaginal microbiota has been linked to higher risk for ovarian cancer.

True or false: Type O...

12/21/2020

Oncology

Test Your Knowledge

Quiz: Does Nivolumab Improve OS Vs Gem/PLD in Platinum-Resistant Ovarian Cancer?

12/11/2020

True or false: Nivolumab improved overall survival versus gemcitabine/pegylated liposomal doxorubicin in platinum-resistant ovarian cancer.

True or false: Nivolumab...

12/11/2020

Oncology

Test Your Knowledge

Quiz: Is Significant Clinical Benefit Derived From Maintenance Olaparib for BRCA-Mutated Ovarian Cancer?

11/10/2020

True or false: Long-term olaparib maintenance significantly extended PFS over placebo in BRCA-mutated ovarian cancer.

True or false: Long-term...

11/10/2020

Oncology

Test Your Knowledge

Quiz: Which Therapy Extended PFS for Ovarian Cancer in the ARIEL3 Study?

10/08/2020

According to the ARIEL3 study, _______ extended PFS for ovarian cancer despite toxicities?

According to the ARIEL3 study,...

10/08/2020

Oncology

Test Your Knowledge

Quiz: Could Cancer Cells in Endometrial Cysts Improve Ovarian Cancer Detection?

09/01/2020

True or False: Endometriosis-associated ovarian cancer often occurs within 36 months of follow-up for endometrial cysts, leading experts to suggest that cancer cells may already be present in endometrial cysts.

True or False:...

09/01/2020

Oncology

Test Your Knowledge

Quiz: Which Combination Benefits Patients with Mesothelin-Expressing Solid Tumors?

08/06/2020

Which combination yielded manageable safety and encouraging antitumor activity in patients with mesothelin-expressing solid tumors?

Which combination yielded...

08/06/2020

Oncology

Test Your Knowledge

Quiz: Long-Term Maintenance Olaparib for BRCA-Mutated, Relapsed Ovarian Cancer?

06/25/2020

True or false: Maintenance olaparib did not provide a significant OS improvement in a phase 3 study of patients with platinum-sensitive, BRCA-mutated, relapsed ovarian cancer.

True or false: Maintenance...

06/25/2020

Oncology

Test Your Knowledge

Quiz: Does Maintenance Pazopanib Improve OS for Advanced Ovarian Cancer?

05/22/2020

True or false: Maintenance pazopanib improved overall survival in advanced ovarian cancer in a phase 3 clinical trial.

True or false: Maintenance...

05/22/2020

Oncology

Test Your Knowledge

Quiz: Efficacy of Gemcitabine–Pazopanib Combo in Ovarian Cancer

04/14/2020

True or False: Adding pazopanib to gemcitabine has been shown to enhance antitumor activity in patients with ovarian cancer.

True or False: Adding pazopanib...

04/14/2020

Oncology

Test Your Knowledge

Quiz: What Yields Better Response Than Chemo in Relapsed Ovarian Cancer?

04/09/2020

Among pretreated patients with relapsed ovarian cancer, what significantly improved PFS vs nonplatinum chemo?

Among pretreated patients with...

04/09/2020

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology